BioSpace News Archive

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, will present updates at the 2022 annual meeting of the American Society for Clinical Oncology in Chicago June 3-7 describing multiple applications for its next-generation liquid biopsy platform.

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that its seven clinical abstracts selected by the 2022 American Society of Clinical Oncology Annual Meeting, of which six were selected for presentations and one was selected for publication-only, have been published on the ASCO’s website.

Iovance Biotherapeutics, Inc. reported clinical results from its C-144-01 clinical study in patients with advanced melanoma who progressed on prior anti-PD-1/L1 therapy, and if BRAF mutation positive, also on prior BRAF or BRAF/MEK inhibitor therapy.

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2022 financial results and provided a corporate update.

Turning Point Therapeutics, Inc. announced that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies Healthcare Conference on June 8 and the 43rd Annual Goldman Sachs Healthcare Conference on June 14.

Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

AB Science SA announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis, meaning that the information and materials submitted by AB Science has been screened and found acceptable for review as a New Drug Submission.

Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that its abstract on a preclinical oncology study for one of Arbutus’ oral PD-L1 inhibitor compounds designed to reawaken the immune system, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), today announced the online publication of the abstract for its lead program, PC14586, accepted as an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting being held June 3-7, 2022 in Chicago, Illinois.

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a Trials in Progress poster presentation at the 2022 American Society of Clinical Oncology Annual Meeting being held in Chicago, IL June 3-7, 2022.